News

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Initial results show promise for Eli Lilly's new weight loss drug
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Clinical Trials Arena on MSN1d
Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss
Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
STAT2d
Eli Lilly’s much-anticipated obesity pill yields modest results
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...
Marketplace2d
Makers of Wegovy, Zepbound face competition from compounding pharmacies
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Devdiscourse1d
Eli Lilly's GLP-1 Pill: A Diminished Competitor in the Obesity Drug Race
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...